Combining chemotherapy and tislelizumab with preoperative split-course hypofraction radiotherapy for locally advanced rectal cancer: study protocol of a prospective, single-arm, phase II trial

Introduction Short-course radiotherapy (SCRT) with systemic therapy has the potential to further improve the long-term efficacy in patients with locally advanced rectal cancer (LARC). To maximise the benefits of neoadjuvant therapy for improved prognosis, it is important to determine the optimal mix of chemotherapy, immunotherapy and SCRT. Methods and analysis Fifty treatment-naïve patients with operable LARC (T3–4 and/or N+) will be recruited. Patients will be synchronously treated with capecitabine plus oxaliplatin (CAPOX) chemotherapy, tislelizumab and preoperative split-course hypofraction radiotherapy (SCHR) (5×7 Gy) before surgery. Chemotherapy for CAPOX starts on day 1 of every 21-day cycle: on day 1, oxaliplatin 130 mg/m2 will be injected intravenously. On days 1–14, capecitabine 1000 mg/m2 was ingested two times a day. Simultaneously, tocilizumab 200 mg will be given intravenously on the first day of every 21-day cycle. A single 7 Gy SCHR treatment (day 7 of each 21-day cycle) will be delivered five times during the seventh day of treatment. The primary endpoint will be pathological complete response. The secondary outcomes will be the 3-year disease-free survival, local recurrence rate, overall survival, sphincter-sparing surgery rate, R0 resection rate, predictive biomarkers and quality of life. Ethics and dissemination The study protocol was approved by the Ethics Committee of Xiehe Affiliated Hospital of Fujian Medical University (XAHFMU) (No. 2021YF025-01). Results from our study will be disseminated in international peer-reviewed journals. All study procedures were developed in order to assure data protection and confidentiality. Trial registration number NCT05176964.

• Publication year

  2023

• Venue

  BMJ Open

• Publication date

  2023-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1136/bmjopen-2022-066976PMID 36927585PMCID 10030573
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase II, single-arm trial of preoperative short-course radiotherapy followed by chemotherapy and camrelizumab in locally advanced rectal cancer

  2021cited by this paper
• SO-30 Efficacy and safety of neoadjuvant short-course radiation followed by mFOLFOX-6 plus avelumab for locally-advanced rectal adenocarcinoma: Averectal study

  2021cited by this paper
• Use of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Initial Results From the Pembrolizumab Arm of a Phase 2 Randomized Clinical Trial.

  2021cited by this paper
• Chemotherapy-based split stereotactic body radiation therapy for borderline resectable and locally advanced pancreatic cancer: study protocol of a prospective, single-arm phase II trial

  2020cited by this paper
• Short-term results of VOLTAGE-A: Nivolumab monotherapy and subsequent radical surgery following preoperative chemoradiotherapy in patients with microsatellite stable and microsatellite instability-high locally advanced rectal cancer.

  2020cited by this paper
• Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors

  2019cited by this paper
• ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach.

  2019cited by this paper
• Immunotherapy in colorectal cancer: rationale, challenges and potential

  2019cited by this paper
• Feasibility of split-course stereotactic ablative radiotherapy for oligometastases

  2018cited by this paper
• Short‐Course Radiotherapy in Neoadjuvant Treatment for Rectal Cancer: A Systematic Review and Meta‐analysis

  2018cited by this paper
• Clinical Outcomes of Image Guided Adaptive Hypofractionated Weekly Radiation Therapy for Bladder Cancer in Patients Unsuitable for Radical Treatment

  2017cited by this paper
• Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial.

  2017cited by this paper
• Impact of 2-staged stereotactic radiosurgery for treatment of brain metastases ≥ 2 cm.

  2017cited by this paper
• Improved Metastasis- and Disease-Free Survival With Preoperative Sequential Short-Course Radiation Therapy and FOLFOX Chemotherapy for Rectal Cancer Compared With Neoadjuvant Long-Course Chemoradiotherapy: Results of a Matched Pair Analysis.

  2017cited by this paper
• Abscopal, immunological effects of radiotherapy: Narrowing the gap between clinical and preclinical experiences

  2017cited by this paper
• Modified FOLFOX6 With or Without Radiation Versus Fluorouracil and Leucovorin With Radiation in Neoadjuvant Treatment of Locally Advanced Rectal Cancer: Initial Results of the Chinese FOWARC Multicenter, Open-Label, Randomized Three-Arm Phase III Trial.

  2016cited by this paper
• Long-course oxaliplatin-based preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase III study.

  2016cited by this paper
• Cancer statistics in China, 2015

  2016cited by this paper
• Split-Course Accelerated Hypofractionated Radiotherapy (SCAHRT): A Safe and Effective Option for Head and Neck Cancer in the Elderly or Infirm.

  2016cited by this paper
• PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.

  2015cited by this paper
• Global cancer statistics, 2012

  2015cited by this paper
• The antitumor immune response generated by fractionated radiation therapy may be limited by tumor cell adaptive resistance and can be circumvented by PD-L1 blockade

  2015cited by this paper
• Cancer statistics, 2015

  2015cited by this paper
• PD-1 blockade in tumors with mismatch repair deficiency.

  2015cited by this paper
• Ablative Tumor Radiation Can Change the Tumor Immune Cell Microenvironment to Induce Durable Complete Remissions

  2015cited by this paper
• The tumor radiobiology of SRS and SBRT: are more than the 5 Rs involved?

  2014cited by this paper
• Five fractions of radiation therapy followed by 4 cycles of FOLFOX chemotherapy as preoperative treatment for rectal cancer.

  2014cited by this paper
• Defining Molecular Signature of Pro-Immunogenic Radiotherapy Targets in Human Prostate Cancer Cells

  2014cited by this paper
• Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade.

  2014cited by this paper
• Radiobiological basis of SBRT and SRS

  2014cited by this paper
• Severe intestinal toxicity after stereotactic ablative radiotherapy for abdominopelvic malignancies

  2013cited by this paper
• Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04.

  2012cited by this paper
• Immunologic correlates of the abscopal effect in a patient with melanoma.

  2012cited by this paper
• Global cancer statistics

  2011cited by this paper
• Split-Course Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer: A Single-Institution Experience of 144 Patients

  2011cited by this paper
• The Confluence of Stereotactic Ablative Radiotherapy and Tumor Immunology

  2011cited by this paper
• Hypofractionation results in reduced tumor cell kill compared to conventional fractionation for tumors with regions of hypoxia.

  2011cited by this paper
• Toxic risk of stereotactic body radiotherapy and concurrent helical tomotherapy followed by erlotinib for non-small-cell lung cancer treatment - case report

  2010cited by this paper
• Regulatory T cells in tumor immunity

  2010cited by this paper
• Immunogenic death of colon cancer cells treated with oxaliplatin

  2010cited by this paper
• Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment.

  2009cited by this paper
• Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial

  2009cited by this paper
• Three-staged stereotactic radiotherapy without whole brain irradiation for large metastatic brain tumors.

  2009cited by this paper
• Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.

  2006cited by this paper
• Long‐term results of a randomized trial comparing preoperative short‐course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer

  2006cited by this paper
• Local Radiation Therapy of B16 Melanoma Tumors Increases the Generation of Tumor Antigen-Specific Effector Cells That Traffic to the Tumor1

  2005cited by this paper
• Preoperative versus postoperative chemoradiotherapy for rectal cancer.

  2004cited by this paper
• Hypofractionated radiotherapy for patients with carcinoma of the bladder.

  1999cited by this paper
• Preoperative hyperthermia combined with radiochemotherapy in locally advanced rectal cancer: a phase II clinical trial.

  1998cited by this paper
• Hypofractionated radiotherapy for muscle invasive bladder cancer in the elderly.

  1997cited by this paper
• Hypofractionated radiotherapy for invasive bladder cancer.

  1997cited by this paper
• Once weekly irradiation for carcinoma of the bladder.

  1996cited by this paper
• Cancer statistics

  1989cited by this paper

• Therapeutic Management of Locally Advanced Rectal Cancer: Existing and Prospective Approaches

  2025cites this paper
• The role of PD-1/PD-L1 signaling pathway in cancer pathogenesis and treatment: a systematic review

  2024cites this paper
• Will personalized ultrafractionated stereotactic adaptive radiotherapy (PULSAR) or split-course SBRT based on systemic therapy (3S) be future directions in the Field of SBRT?

  2024cites this paper
• GSK484, an inhibitor of peptidyl arginine deiminase 4, increases the radiosensitivity of colorectal cancer and inhibits neutrophil extracellular traps

  2023cites this paper
• Perioperative immune checkpoint inhibition for colorectal cancer: recent advances and future directions

  2023cites this paper